Lupin gets UDFDA nod for generic version of Pfizer’s acne drug

Pharma company Lupin said it received final approval from the US Food and Drug Administration for launching a generic version of Pfizer Inc.’s acne drug Vibra-Tabs.

Doxycycline Hyclate Tablet 100 mg had US sales of USD 149.9 million per year, the company said.

Doxycycline Hyclate is the AB rated generic equivalent of Pfizer Inc.’s Vibra-Tabs.

It is used for the treatment of infections caused by various microorganisms and as an adjunctive therapy in Severe acne.

Lupin is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-infective and NSAID space.

It is also a global leader in anti-TB drugs.

It is the 6th largest generics pharmaceutical company in the world by revenue and 4th largest pharmaceutical player in the US by prescriptions.

It is also the sixth largest generic pharmaceutical player in Japan and the sixth largest company in Indian Pharmaceutical Market.